Find a Clinical Trial

Showing 141 - 150 of 174 Trials

  • A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy ofLY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing TumorCells, in Participants with Selected Advanced Solid Tumors

    Principal Investigator:

    Lanyi Nora Chen, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07046923

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to learn about the effects of the study drug, LY4175408, to find the best dose for treating advanced/metastatic (meaning the cancer has spread beyond where it started to other parts of the body) cancers and to see how safe LY4175408 is for patients with advanced/metastatic cancers. LY4175408 is an “investigational” drug in this study because it has not been approved by The United States Food and Drug Administration (FDA), the health authority that gives approval for new medicines in the United States. Are you Eligible? (Inclusion Criteria) Is ≥18...

  • A Phase 1 study of JNJ-95437446 in adult participants with advanced-stage solid tumors

    Principal Investigator:

    Lanyi Nora Chen, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07107230

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to investigate if the study drug JNJ-95437446 is safe and effective in treating patients with advanced-stage non-small cell lung cancer, colorectal cancer, and head and neck squamous cell cancer. This study will also find out if JNJ-95437446 can cause side effects. Side effects are unexpected or unwanted reactions from taking a drug. Another purpose is to find out how long JNJ-95437446 stays in your body and how your body responds to it. Are you Eligible? (Inclusion Criteria) Must be 18 years of age or older - Must be diagnosed with metastatic non-small cell lung...

  • A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 asMonotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07277413

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine the ideal dose of the study drugs, IDE892 by itself and IDE892 in combination with IDE397, and to find out what effect, good and/or bad, these study drugs may have on your cancer. This will be first human study for IDE892. Both IDE892 and IDE397 has not been approved by the United States (US) Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must be willing and able to provide blood/tumor tissue samples for biomarker testing - Must be able to swallow and retain the study drug

  • An open-label, Phase 1b study to evaluate the safety andtolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma or astrocytoma

    Principal Investigator:

    Maria Diaz Ordonez, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05879367

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to measure how safe eflornithine is in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM) following radiation therapy. Safety and tolerability will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study.This study will also measure levels of eflornithine in patients following dosing, and it will evaluate how effective eflornithine is as a treatment of GBM when combined with temozolomide. Eflornithine is an experimental drug, which means that it...

  • A MULTICENTER, OPEN-LABEL PHASE 1/1B/PHASE 2DOSE-FINDING, SAFETY, AND PHARMACOKINETICSTUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYLAURISTATIN E (MMAE) ANTIBODY DRUGCONJUGATE, IN ADVANCED REFRACTORYSOLID TUMORS

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06014658

    Population:

    Adult

    Phase:

    I
    The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans. Are...

  • A Phase 1 Study of PF-08046040/SEA-CD70 in MyeloidMalignancies

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04227847

    Population:

    Adult

    Phase:

    I
    You are being asked to participate in this study because you have Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and we are testing the study drug’s, SEA-CD70, to find out what its side effects are and to see if the study drug is safe for people with these types of cancer. are testing to see if SEA- CD70 is safe for people, and its side effects. SEA-CD70 is a type of drug called an antibody. Antibodies are part of your immune system. Usually they help protect you from getting sick. The purpose of this study is to use study drug SEA-CD70, and while using another antibody...

  • A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

    Principal Investigator:

    Peter Chei-Way Pan, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06860594

    Population:

    Adult

    Phase:

    I
    Researchers recently found that triapine can make radiation therapy work better against glioblastoma cells and in mice with glioblastoma. Tumors did not grow for a longer time after treatment with triapine along with radiation compared to radiation alone. Triapine has also been tested in people with other types of cancers and has been found to be safe. This study is being done to answer the following question: What is the highest dose of triapine that can be safely and tolerably taken in combination with radiation therapy in patients with recurrent glioblastoma or astrocytoma? We are doing...

  • CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against Tcell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial

    Principal Investigator:

    Ran Reshef, MD, MSc

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06420089

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test whether Senza5 CART5 is safe to give to participants with T-cell non-Hodgkin lymphoma (NHL). The study will also test how Senza5 CART5 cells affect your cancer and how long they survive in your body. It will take some of your white blood cells, called T cells, and modify them with the hopes that they target the cancer cells or cells that help the cancer to grow. The change involves adding or altering the genes in your T cells, which are part of your immune system. The modified cell product given in this study is called Senza5 CART5. Senza5 CART5 is...

  • CHRONIC CONVECTION ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT MALIGNANT GLIOMA

    Principal Investigator:

    Jeffrey N Bruce, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06666712

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine the safety of directly injecting a chemotherapy drug called Topotecan and a contrast agent called Gadolinium into malignant brain tumors. Currently there is no effective treatment for recurrent malignant brain tumors, which means the brain tumor has returned after the original tumor has been treated. Most systemic chemotherapy drugs have toxic side effects, which make them difficult to use for brain tumors. However, we are doing this study to find out if using an experimental method of directly infusing the drug into the tumor, allows research...

  • First-in-Human, Phase 1/1b, Open-label, Multicenter Study ofBifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapyand in Combination Therapy in Patients with EGFR-DrivenAdvanced Solid Tumors

    Principal Investigator:

    Catherine Shu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04429542

    Population:

    Adult

    Phase:

    I
    This is a first-in-human clinical research study. This study is sponsored by a biopharmaceutical company named Bicara Therapeutics. The main purpose of this study is to investigate the study drug BCA101 alone and BCA101 in combination with pembrolizumab for its safety, the way the body absorbs, distributes, and gets rid of this study drug, how the study drug acts on the body, and whether it works on your cancer in patients with advanced cancer like you. Subjects will receive either BCA101 alone or BCA101 in combination with pembrolizumab until disease worsens, the subject stops benefitting...

Pages

Back to top